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Introduction 
The aim of this paper is to outline the salient feature of meta-analysis in order to indicate how 
this approach can draw together conclusions about gestational diabetes mellitus (GDM) that 
are not otherwise obvious or strengthen results that might not otherwise be compelling.  
 
It is of interest to note in passing that the official runners-up for the Nobel Prize in Physiology 
or Medicine in 2008 were Professor Rory Collins and Sir Richard Peto of the University of 
Oxford for their contributions to clinical medicine and epidemiology through the development 
and application of meta-analysis.  
 
Meta-analysis as a tool 
Meta-analysis is a statistical approach which codes empirical studies of a topic to permit 
comparison of data, and occasionally enables one to combine the data (Shannon [32]). Thus, 
Glass [12], the effective founder of meta-analysis, defines it as “the statistical analysis of a 
large collection of analysis results from individual studies for the purpose of integrating the 
finding”. 
 
There are a number of other ways of combining results of independent studies. One general 
approach is by combining the probabilities obtained from a number of studies which are 
testing the same directional hypothesis. Probably the most famous of these is Fisher’s method 
of adding the logarithms of probabilities [22]. It suffers from two drawbacks though: one is 
that it can yield results that are inconsistent with such overall tests as the sign test; the other is 
that it can support significant but contradictory results. Another way of combining 
probabilities is Edgington’s method [9] but it is restricted to small sets of studies.  
 
That it is not more popular to attempt systematic efforts at synthesis is something of a puzzle, 
and Pillemer and Light [30] suggest an explanation based on prestige: “The biggest rewards 
in most academic disciplines have traditionally gone to researchers who begin the exciting 
new experiment, or design the successful new curriculum, or develop the broad new theory. 
In contrast, pulling together existing evidence is not considered a truly scientific activity by 
some because it deals with old data. We disagree. Perhaps the key idea in all of this is   BIOAUTOMATION, 2009, 13 (2), 73-83 
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‘discovery’. A systematic effort to draw conclusions from many existing studies can be every 
bit as likely to lead to a ‘discovery’…as one new study. ” The question of how compelling the 
evidence has to be in order to be convincing is discussed by Choy and Shannon [4].  
 
Peto [26] outlined the objectives of meta-analysis in medicine as: 
•  To demonstrate an effect in a direction of interest by overcoming the obscuring effect 
of sampling variations in a large number of small studies; 
•  To add quantitative effect sizes (and their uncertainty) to the qualitative results of 
traditional narrative literature reviews; and 
•  To encourage systematic collation and review of individual studies and explicit 
reporting of the criteria used.  
 
Effect sizes can be calculated in a variety of ways, depending on how the original results were 
reported. For example, 
•  δ =
µT −µC ()
σC
 if the means are given; 
•  δ = t
1
nT
−
1
nc  
for t-test designs; 
•  δ = 2
F
nT + nc  
for one-way ANOVA designs; 
•  δ = tg 21−rxy ()
1
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1
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for raw gain scores.  
 
It is becoming customary in meta-analyses of medical literature to qualify trends with the 
quality of evidence ratings as described in Choy and Shannon [3]. Table 1 indicates the levels 
of evidence of the papers referred to in this meta-analysis. Level I is the most scientifically 
stringent, though often impractical with long-term chronic illnesses.  
 
Table 1. Quality of evidence for meta-analysis in this study 
Levels Controlled  Trials  No.  of 
Papers 
I  A systematic review of all relevant randomized controlled trials  4 
II  At least one properly-designed randomized controlled trial  55 
IIIA  Well-designed but not randomized, controlled trials 
IIIB  Well-designed cohort or case-control analytic studies 
IIIC Multiple  time-series  with or without intervention 
 
39 
IV  Opinions of experts based on clinical experience or descriptive 
studies 
5 
 
More specifically in diagnostic testing, Irwig et al [15] claimed that meta-analysis can: 
•  Provide an overall summary of diagnostic accuracy; 
•  Determine whether estimates of diagnostic accuracy depend on the study design 
characteristics (study validity) of the primary studies; 
•  Determine whether diagnostic accuracy differs in the subgroups defined by the 
characteristics of the patients and test; and 
•  Identify areas for further research.  
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                             Table 2. The issues in the papers considered in this meta-analysis 
Paper  Number    1 2 3 4 5  6 7  8 
Pages  2 2 2 1 9  2 14 8 
References  24 27 43 4  103 20 41  63 
Evidence Quality  IV IV IV IV IIIB IV IIIA  IIIB 
Macrosomia  1 0 0 1 0  1 1  0 
Perinatal  Mortality  0 0 1 1 0  0 0  0 
Screening  &  Diagnosis  1 1 0 1 1  1 1  1 
Follow-up  Study  0 0 0 1 1  0 0  1 
Insulin  Sensitivity  0 0 0 0 1  0 0  0 
Complications  0 0 0 0 1  0 0  0 
Offspring→DM  0 0 0 0 1  0 0  0 
Mother→DM  0 0 0 0 1  0 0  0 
General: history/definition 0 0 0 0 1  1 0  0 
Diagnostic  Test  Only  0 0 0 0 0  0 1  0 
Treatment/Management  0 0 0 0 0  0 0  1 
Control  Issues  0 0 0 0 0  0 0  1 
Tables/Figures  0 0 0 0 T  0 T  T 
Special  Paper  0 0 0 0 1  0 1  0 
 
Gestational Diabetes Mellitus 
The National Diabetes Data Group [23] defined the gestational diabetes mellitus (GDM) as 
carbohydrate intolerance of variable severity first diagnosed during pregnancy, and Metzger 
et al [19] noted that the definition applies whether or not insulin is used for treatment or the 
condition persists after pregnancy. Hod et al [14] carried out an extensive literature review to 
answer three questions (although they did not answer the third): 
1.  Is the condition important, namely is GDM significantly related to maternal and 
perinatal morbidity and mortality? 
2.  Is the accepted intervention (treatment modalities) effective in reducing these 
complications? 
3.  Are there effective diagnostic tests available for this condition? 
 
We shall also address the substance of these three questions, albeit in a slightly different way. 
It is therefore worth noting the conclusion of Hod et al [17] that “GDM is not merely a 
clinical sign but a disease, a distinct clinical entity, with short-rang and long-range 
implications for both mother and offspring. ” 
 
In an earlier paper Coustan [6] had noted that international agreement was lacking about 
diagnostic criteria for gestational diabetes mellitus (GDM) and its treatment, and that there 
was debate whether gestational diabetes was a disease or merely a risk factor. The issue has 
been further confounded by the metabolic changes brought about by pregnancy which can 
have the effect of increasing the glucose response to a pure carbohydrate challenge even 
though fasting levels in pregnant women are lower than in non-pregnant people [6]. 
Nevertheless, there is general agreement that this pregnancy condition can be linked to 
adverse pregnancy outcomes and may be associated with subsequent diabetes in the non-
pregnant state [6]. Accordingly, the criteria for this study are based on a systematic review of 
the literature to identify papers for the review which deal with: 
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a.  the conversion of the mother with GDM to NIDDM; 
b.  the fetal and maternal outcomes; 
c.  results of the international symposia in 1980, 1984 and 1990; 
d.  the Australian diagnostic criteria; 
e.  multi-level selection according to: 
•  population effect; 
•  study type; and 
•  study specific parameters.  
 
GDM Meta-analysis 
A 10 step procedure was followed in conducting the meta-analysis in this paper.  
1.  Development of a protocol for conducting the meta-analysis.  
2.  Identification of sources of information used.  
3.  Definition of the criteria for the selection of trials for inclusion: 
• Relevance: 
o  Construct validity (the theoretical framework);  
o  Eternal validity (the selection of subjects: random or convenience); 
• Acceptability: 
o  Internal validity (does or can the study do what it tires to do?); 
o  Statistical validity (appropriateness of statistics).  
4.  Reading, classification, coding, scoring, evaluating, and choosing of papers.   
The coding scheme used by Shannon and Hung [33] has been adapted for this study, 
namely: 
• Ecological  features 
o  Treatment variables 
o  Disease variable  initial state conditions 
• Methodological  features 
o  Assignment of patients 
o  Controls 
−  Experimenter effects 
−  Historical effects 
−  Measuring bias 
−  Author bias 
o  Strength of research design 
• Statistical  features 
o  Subject variables 
−  Age 
−  Sex 
−  Risk factors 
−  Socio-economic status 
−  Ethnic/racial/geographic variables 
o  Appropriateness of statistics 
o  Data 
• Publication  features 
o  References 
o  Sources of references if unpublished 
o  Type of report 
−  Abstract 
−  Review   BIOAUTOMATION, 2009, 13 (2), 73-83 
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−  Letter 
−  Conference paper 
−  Editorial 
o  Year(s) of publication 
−  Thesis 
−  Internal report 
−  External report 
−  Journal article 
−  Published by learned society 
o  name of publication 
5.  Adjudication of differences among the three readers on qualitative criteria.  
6.  Development of questions, procedures, and analyses to pose of trials for inclusion.  
7.  Reading of papers and answering of questions on the checklists.  
8.  Adjudication of differences which could not be reconciled among the three scorers on the 
quantitative measurements.  
9.  Combination of results an quality-assurance of the data.  
10. Analysis, interpretation and reporting of results.  
 
Thus a Medline key-words search from 1966 to 1996 came up with the numbers of references 
listed in Table 3.  
                                                                                     Table 3. Medline Search of Keywords 
Years  Diagnosis GDM Screening Diagnosis & GDM Screening & GDM
1992-1996  74441 133 20485  24  46 
1986-1991 102640  126  22917  18  29 
1980-1985  66414 30 11832  7  5 
1976-1979 36038  4  5924  0  0 
1966-1975 41444  0  5011  0  0 
 
Given the relatively small number of published papers on screening and diagnosis of GDM; 
the likelihood of extensive quantitative combination of odds ratios or effect sizes was low. 
Accordingly, a sweeping search of the literature was made on the basis of Fig. 1 in order to 
attempt some qualitative coding and comparisons.  
 
Fig. 1 Review plan 
Nevertheless, much of the literature was not amenable to comination of quantitative results 
even when the conclusions could be compared qualitatively because they lacked adequate 
controls or they were a mixture of longitudinal and cross-sectional designs. Furthermore, on a 
few occasions we found that some references which were cited in support of a position when   BIOAUTOMATION, 2009, 13 (2), 73-83 
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examined closely either did not have anything to say on the details of the subject in question 
or were only marginly related to it. Such situations obviously complicated our searching and 
sorting processes.  
 
An investigation of the literature relating to the existence and diagnosis of GDM helped us 
reach the following conclusion, which is included without discussion as an example.  
 
Conclusion 1  Quality  
of Evidence 
The criteria for Gestational Diabetes Mellitus should be a fasting plasma 
glucose level ≥ 5. 5 mmol/1 and/or a plasma glucose level ≥ mmol/1 2 hours 
after a 75g OGTT administered according to the WHO criteria.  
II/III
1 
 
Management of GDM 
O’Sullivan et al [24], in a prospective study of 187 GDMs 259 randomly selected controls, 
found significantly higher perinatal mortality rates among the GDMs, with age having a 
disproportionately adverse effect, enhanced slightly by obesity (Table 4).  
 
                                               Table 4. Comparisons among pregnant women 
Characteristic PDM
2 GDM NonDM 
Delivery < 37 wk(%)  14  10  6 
Macrosomia (%)  40  23  11 
FPG (mmol/1) 2
nd Trimester 7. 0  5. 7  4. 1 
FPG (mmol/1) 3
rd Trimester  5. 8  5. 1  4. 2 
 
 
Fig. 2 
 
The uncertainty about risk factors outlined above gives support to a healthy life style strategy 
as a means of multiple risk factor approach to GDM as has been suggested for NIDDM in 
general [17, 34]. The results of Sells et al [31] also indicated that mothers with IDDM “who 
maintain good control during pregnancy can expect to have infants who are neuro-
developmentally normal”.  
 
                                                   
1 Most studies were cross-sectional observational studies, with the general consensus in favour of the WHO 
criteria because they pick up more cases of GDM than NDDG criteria. 
2 Pregestational Diabetes   BIOAUTOMATION, 2009, 13 (2), 73-83 
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This has been a situation of some confusion as there has been a view that pregnant women 
should not diet as there was a risk that cutting food intake would lead to the loss of essential 
nutrients to help the baby’s development and growth. There seems to have been a large 
increase in obese women of reproductive age over the past decade. This growing group of 
women often need intensive antenatal care, bariatric-sized beds and are difficult to care 
physically during labour. Evidence is accumulating that shedding kilos may not only do no 
harm to mother and child but might benefit them [35] 
 
 
Fig. 3 
 
Conclusion 2  Quality  
of Evidence 
The fetal outcomes of undiagnosed or poorly managed GDM include double 
the risk of large for gestational age and one and a half times the risk of 
macrosomia (birthweight > 4000g).  
III
3 
 
 
 
Fig. 4. Boxplot of Diet vs Diet+Insulin (%) 
 
Tight glycaemic control is the first requirement of the management of GDM. Two ways of 
doing this are diet and exercise, both of which were studied by Jovanovic-Peterson and 
Peterson [25] who found each effective in reducing FBG over a six week period. Not 
surprisingly both together were found to be more effective, although the study of Maresh et al 
[18] found no statistically significant difference between the two therapies.  
                                                   
3 The issue is complicated by women without hyperglycaemia who have large babies.   BIOAUTOMATION, 2009, 13 (2), 73-83 
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Fig. 4 shows that there is a definite trend, though the data are not robust enough for more 
sophisticated statistical analysis.  
 
Conclusion 3  Quality  
of Evidence 
Properly-diagnosed and well-managed GDM ‘normalises’ the relative risks 
associated with GDM, except for caesarean delivery.  
II 
 
Concluding comments 
Superficially meta-analysis seems just like a very careful traditional literature review. The 
differences are in the structure, the coding, the qualification and the quantification of the 
results. In fact some medical journals (for example, journals of the American Medical 
Association) are sufficiently aware of the differences to the extent that they require literature 
reviews to be done with meta-analysis.  
 
Although the extrapolation from animal studies to human hypotheses is problematic, animal 
experiments do abound to the extent that they at least suggest reasonable comparisons with 
human epidemiological data about any abnormal intra-uterine environment, and this is an 
issue which is intimately bound up with any suggestions about the management of GDM. 
Animal experiments are also of use because they can remove the clinical ‘noise’ from 
analysis. In fact, animal experiments are unequivocal about the adverse intra-uterine effect of 
undiagnosed or poorly managed GDM on the subsequent development of the offspring [27, 
28]. This has important lifestyle consequences for public health planning by governments [2, 
11].  
 
Notwithstanding these recommendations, confirmation of diabetes at any stage during or 
subsequent to pregnancy should not be precluded if there are clinical features to warrant such 
a diagnosis, because the issues examined here are not unrelated to the world wide increase in 
Type 1 and Type 2 diabetes mellitus in childhood [36]. Moran and Teede [21] note that “there 
is emerging evidence that modifying diet composition has beneficial effects on weight loss 
and metabolic risk factors, but this approach needs to be successful and safe within a long-
term sustainable lifestyle modification setting for the optimal treatment of IR (insulin 
resistance). ” This accords well with our recommendations.  
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